National and Kapodistrian University of Athens
Μελέτη επίδρασης φυτικών παραγόντων στη μη-αλκοολική νόσο του ήπατος
Abstract
dc:descriptionIntroduction: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries, with increasing prevalence attributed to rising obesity rates, diabetes mellitus, and metabolic syndrome. NAFLD encompasses a spectrum of clinical manifestations ranging from hepatic steatosis to more severe conditions such as non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis or hepatocellular carcinoma. The pathophysiology of NAFLD is multifactorial, primarily involving insulin resistance, oxidative stress, and inflammation. The aim of this study was to investigate the effects of natural compounds silibinin and quercetin on NAFLD, emphasizing the reduction of steatohepatitis and NAFLD Activity Score (NAS), and evaluating molecular markers of autophagy through immunohistochemistry and Western blot analysis. Materials & Methods: Seventy-one male C57BL/6J (wild type) mice were subjected to NAFLD induction through a high-fat diet (HFD) for 12 weeks. The animals were then randomized into six groups. The first group was euthanized after 12 weeks (Baseline, n=11). The remaining mice continued on HFD for additional 4 weeks, receiving the fol-lowing interventions: a. water for injection (Control, n=12), b. SLB-HP-β-CD at 2.5 mg/kg (SLB1, n=12), c. SLB-HP-β-CD at 5 mg/kg (SLB2, n=12), d. QUE-HP-β-CD at 10 mg/kg (QUE, n=12), e. HP-β-CD at 46.67 mg/kg (HP-β-CD, n=12). Liver tissues underwent histological analysis for NAFLD Activity Score (NAS) assessment. Immunohistochemical analysis and Western blot analysis followed to evaluate key biomarkers for autophagy and lipid metabolism regulation (Beclin1, LCA, SQSTM1, PLIN3, CD36). Results: Low-dose silibinin treatment reduced NAS from 5.83±1.27 to 5.42±1.17, while high-dose silibinin further decreased NAS to 4.50±1.57. Steatohepatitis incidence significantly decreased from 83.3% in the control group to 50% in the low-dose group and 33.3% in the high-dose group. Quercetin treatment also reduced NAS to 4.75±1.06, with steatohepatitis incidence significantly reduced to 33.3%. Beclin1 exhibited strong expression in 74.6% of the animals, with no significant difference among groups. In contrast, LC3 expression was significantly lower in animals with NASH (OR: 0.14, 95% CI: 0.05–0.40, p<0.01). SQSTM1 showed significantly stronger expression in animals with fatty liver compared to those with NASH (OR: 4.50, 95% CI: 1.63–12.39, p<0.01). PLIN3 expression remained stable across groups, whereas CD36 showed a non-significant trend towards increased weak expression in NASH.In Western blot analysis, LC3A-I was primarily detected in the cytoplasmic fraction (SP). Conversely, LC3B-I was detected in both cellular fractions across all groups, with LC3B-II primarily localized in the P fraction. SQSTM1 expression significantly increased in the P fraction of the Control and QUE groups, while a significant decrease was observed in the SP fraction of the SLB1 group. Conclusions: Silibinin and Quercetin demonstrate significant therapeutic efficacy against NAFLD, reducing hepatic steatosis and disease severity. These compounds represent promising therapeutic options for managing NAFLD by enhancing autophagy. Further research is required to clarify the molecular mechanisms of their action and to determine optimal dosing for clinical application.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katsaros, Ioannis
- Κατσαρός, Ιωάννης
Subjects
dc:subject × 21- Λιπώδες ήπαρ
- Μη-αλκοολική λιπώδης νόσος ήπατος
- NAFLD
- MASLD
- Σιλιμπινίνη
- Κερκετίνη
- Αυτοφαγία
- Fatty liver
- Silibinin
- Quercetin
- Autophagy
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Κλινική Ιατρική
- Χειρουργική
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
- Clinical Medicine
- Surgery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60643